Li Hong-Bo, Chen Jun-Kai, Su Ze-Xin, Jin Qing-Lin, Deng Li-Wen, Huang Gang, Shen Jing-Nan
Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Cancer Cell Int. 2021 Dec 25;21(1):706. doi: 10.1186/s12935-021-02411-y.
Osteosarcoma is the most common primary bone tumor in children and adolescents. However, some patients with osteosarcoma develop resistance to chemotherapy, leading to a poor clinical prognosis. Hence, effective therapeutic agents that can improve the response to chemotherapy drugs to improve the prognosis of patients with osteosarcoma are urgently needed. Cordycepin has recently emerged as a promising antitumor drug candidate. This study aims to explore the effect of cordycepin in suppressing osteosarcoma in vivo and in vitro and the synergistic effect of cordycepin combined with cisplatin and to demonstrate the underlying molecular mechanism.
CCK-8 assay was performed to investigate the inhibition effect of cordycepin combined with cisplatin in osteosarcoma cell lines. The colony formation and invasion abilities were measured by colony formation assay and Transwell assay. Osteosarcoma cells apoptosis was detected by flow cytometry. Western blot analysis were used to detect the expression of cell apoptosis-related proteins and AMPK and AKT/mTOR signaling pathway-related proteins. Finally, we performed the in vivo animal model to further explore whether cordycepin and cisplatin exert synergistic antitumor effects.
Notably, we found that treatment with cordycepin inhibited cell proliferation, invasion, and induced apoptosis in osteosarcoma cells in vitro and in vivo. Moreover, the combination of cordycepin and cisplatin led to marked inhibition of osteosarcoma cell proliferation and invasion and promoted osteosarcoma cell apoptosis in vitro and in vivo. Mechanistically, we demonstrated that cordycepin enhanced the sensitivity of osteosarcoma cells to cisplatin by activating AMPK and inhibiting the AKT/mTOR signaling pathway.
In brief, this study provides comprehensive evidence that cordycepin inhibits osteosarcoma cell growth and invasion and induces osteosarcoma cell apoptosis by activating AMPK and inhibiting the AKT/mTOR signaling pathway and enhances the sensitivity of osteosarcoma cells to cisplatin, suggesting that cordycepin is a promising treatment for osteosarcoma.
骨肉瘤是儿童和青少年中最常见的原发性骨肿瘤。然而,一些骨肉瘤患者会对化疗产生耐药性,导致临床预后不良。因此,迫切需要有效的治疗药物来提高对化疗药物的反应,以改善骨肉瘤患者的预后。虫草素最近成为一种有前景的抗肿瘤药物候选物。本研究旨在探讨虫草素在体内外抑制骨肉瘤的作用以及虫草素与顺铂联合的协同作用,并阐明其潜在的分子机制。
采用CCK-8法研究虫草素联合顺铂对骨肉瘤细胞系的抑制作用。通过集落形成试验和Transwell试验检测集落形成和侵袭能力。采用流式细胞术检测骨肉瘤细胞凋亡。用蛋白质免疫印迹分析检测细胞凋亡相关蛋白以及AMPK和AKT/mTOR信号通路相关蛋白的表达。最后,我们建立体内动物模型以进一步探究虫草素和顺铂是否发挥协同抗肿瘤作用。
值得注意的是,我们发现虫草素处理在体外和体内均能抑制骨肉瘤细胞的增殖、侵袭并诱导其凋亡。此外,虫草素与顺铂联合在体外和体内均能显著抑制骨肉瘤细胞的增殖和侵袭,并促进骨肉瘤细胞凋亡。机制上,我们证明虫草素通过激活AMPK和抑制AKT/mTOR信号通路增强了骨肉瘤细胞对顺铂的敏感性。
简而言之,本研究提供了全面的证据表明虫草素通过激活AMPK和抑制AKT/mTOR信号通路抑制骨肉瘤细胞生长和侵袭并诱导骨肉瘤细胞凋亡,且增强了骨肉瘤细胞对顺铂的敏感性,表明虫草素是一种有前景的骨肉瘤治疗药物。